We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease.
- Authors
Appleton, Ellen; Khosousi, Shervin; Ta, Michael; Nalls, Michael; Singleton, Andrew B.; Sturchio, Andrea; Markaki, Ioanna; Paslawski, Wojciech; Iwaki, Hirotaka; Svenningsson, Per
- Abstract
A recent study investigated the potential of DOPA decarboxylase (DDC) as a biomarker for Parkinson's disease (PD). The study found that elevated levels of DDC in the cerebrospinal fluid (CSF) could effectively diagnose early, untreated PD, even before a formal diagnosis. However, DDC levels in plasma were only effective in discriminating between treated PD patients and controls. The study suggests that CSF DDC levels could be a valuable biomarker for identifying patients suitable for clinical trials.
- Subjects
PARKINSON'S disease; ALZHEIMER'S disease; LEWY body dementia; PARKINSONIAN disorders; CEREBROSPINAL fluid
- Publication
Translational Neurodegeneration, 2024, Vol 13, Issue 1, p1
- ISSN
2047-9158
- Publication type
Article
- DOI
10.1186/s40035-024-00421-0